Literature DB >> 25786586

Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.

Katarzyna Bal1, Izabela Kałuzińska-Parzyszek, Agnieszka Sobocińska, Daniela Podlecka, Joanna Jerzyńska, Iwona Stelmach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25786586     DOI： 10.1007/s12098-015-1731-5

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  5 in total

1.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors:  Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

2.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

3.  Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Authors:  A Martin; L Lavoie; M Goetghebeur; R Schellenberg
Journal:  Transfus Med       Date:  2012-11-20       Impact factor: 2.057

4.  Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.

Authors:  Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grimbacher; Stephen Jolles; Othmar Zenker; Jutta Neufang-Hueber; Bernd Belohradsky
Journal:  J Clin Immunol       Date:  2011-06-15       Impact factor: 8.317

5.  Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment.

Authors:  Teresa Espanol; Johan Prevot; Jose Drabwell; Seema Sondhi; Laurence Olding
Journal:  Patient Prefer Adherence       Date:  2014-05-02       Impact factor: 2.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.